Patients with cancer are at increased risk for developing infectious complications during the course of their disease and treatment. The following sections of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prevention and Treatment of Cancer-Related Infections provide an overview of the risk factors for infectious complications, recommendations for infectious risk categorization, and strategies for prevention of infections in high-risk patient populations with cancer. Individualized risk evaluation for infections and incorporation of preventative measures are essential components of the overall spectrum of cancer care, and may contribute to optimizing treatment outcomes for patients.

  • 1

    AquinoVMHerreraLSandlerESBuchananGR. Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer. Cancer2000;88:17101714.

    • Search Google Scholar
    • Export Citation
  • 2

    FreifeldAGWalshTMarshallD. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol1995;13:165176.

    • Search Google Scholar
    • Export Citation
  • 3

    HidalgoMHornedoJLumbrerasC. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer1999;85:213219.

    • Search Google Scholar
    • Export Citation
  • 4

    HughesWTArmstrongDBodeyGP. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis2002;34:730751.

    • Search Google Scholar
    • Export Citation
  • 5

    KernWVComettaADe BockR. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med1999;341:312318.

    • Search Google Scholar
    • Export Citation
  • 6

    MalikIAAbbasZKarimM. Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet1992;339:10921096.

    • Search Google Scholar
    • Export Citation
  • 7

    PizzoPA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med1993;328:13231332.

  • 8

    RolstonKVRubensteinEBFreifeldA. Early empiric antibiotic therapy for febrile neutropenia patients at low risk. Infect Dis Clin North Am1996;10:223237.

    • Search Google Scholar
    • Export Citation
  • 9

    SchimpffSC. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med1986;80:1320.

  • 10

    TalcottJAFinbergRMayerRJGoldmanL. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med1988;148:25612568.

    • Search Google Scholar
    • Export Citation
  • 11

    TalcottJASiegelRDFinbergRGoldmanL. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol1992;10:316322.

    • Search Google Scholar
    • Export Citation
  • 12

    TalcottJAWhalenAClarkJ. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol1994;12:107114.

    • Search Google Scholar
    • Export Citation
  • 13

    MihuCNSchaubJKeshS. Risk factors for late Staphylococcus aureus bacteremia after allogeneic hematopoietic stem cell transplantation: a single-institution, nested case-controlled study. Biol Blood Marrow Transplant2008;14:14291433.

    • Search Google Scholar
    • Export Citation
  • 14

    NeofytosDHornDAnaissieE. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis2009;48:265273.

    • Search Google Scholar
    • Export Citation
  • 15

    RizzoJDWingardJRTichelliA. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant2006;12:138151.

    • Search Google Scholar
    • Export Citation
  • 16

    SullivanKMDykewiczCALongworthDL. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology Am Soc Hematol Educ Program2001:392421.

    • Search Google Scholar
    • Export Citation
  • 17

    GriffithsHLeaJBunchC. Predictors of infection in chronic lymphocytic leukaemia (CLL). Clin Exp Immunol1992;89:374377.

  • 18

    SavageDGLindenbaumJGarrettTJ. Biphasic pattern of bacterial infection in multiple myeloma. Ann Intern Med1982;96:4750.

  • 19

    MolteniANosariAMontilloM. Multiple lines of chemotherapy are the main risk factor for severe infections in patients with chronic lymphocytic leukemia with febrile episodes. Haematologica2005;90:11451147.

    • Search Google Scholar
    • Export Citation
  • 20

    PerkinsJGFlynnJMHowardRSByrdJC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer2002;94:20332039.

    • Search Google Scholar
    • Export Citation
  • 21

    DiNubileMJ. Fever and neutropenia: still a challenge. Contemp Intern Med1995;7:3537.

  • 22

    FreifeldAGBowEJSepkowitzKA. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis2011;52:e5693.

    • Search Google Scholar
    • Export Citation
  • 23

    RolstonKV. The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments. Clin Infect Dis2004;39(Suppl 1):S4448.

    • Search Google Scholar
    • Export Citation
  • 24

    GersonSLTalbotGHHurwitzS. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med1984;100:345351.

    • Search Google Scholar
    • Export Citation
  • 25

    BodeyGPBuckleyMSatheYSFreireichEJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med1966;64:328340.

    • Search Google Scholar
    • Export Citation
  • 26

    BochudPYCalandraTFrancioliP. Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med1994;97:256264.

  • 27

    EngelhardDElishoovHOrR. Cytosine arabinoside as a major risk factor for Streptococcus viridans septicemia following bone marrow transplantation: a 5-year prospective study. Bone Marrow Transplant1995;16:565570.

    • Search Google Scholar
    • Export Citation
  • 28

    Gonzalez-BarcaEFernandez-SevillaACarratalaJ. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis1996;15:291296.

    • Search Google Scholar
    • Export Citation
  • 29

    RossettiFCesaroSPuttiMCZanescoL. High-dose cytosine arabinoside and viridans streptococcus sepsis in children with leukemia. Pediatr Hematol Oncol1995;12:387392.

    • Search Google Scholar
    • Export Citation
  • 30

    ChenYKHouHAChowJM. The impact of oral herpes simplex virus infection and candidiasis on chemotherapy-induced oral mucositis among patients with hematological malignancies. Eur J Clin Microbiol Infect Dis2011.

    • Search Google Scholar
    • Export Citation
  • 31

    EpsteinJBHancockPJNantelS. Oral candidiasis in hematopoietic cell transplantation patients: an outcome-based analysis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod2003;96:154163.

    • Search Google Scholar
    • Export Citation
  • 32

    KalhsPKierPLechnerK. Functional asplenia after bone marrow transplantation. Ann Intern Med1990;113:805806.

  • 33

    Centers for Disease Control and Prevention. Recommended Adult Immunization Schedule—United States 2010. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5901a5.htm. Accessed October 16 2012.

    • Search Google Scholar
    • Export Citation
  • 34

    AnaissieEJKontoyiannisDPO’BrienS. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med1998;129:559566.

    • Search Google Scholar
    • Export Citation
  • 35

    MorrisonVARaiKRPetersonBL. Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol2001;19:36113621.

    • Search Google Scholar
    • Export Citation
  • 36

    AnaissieEKontoyiannisDPKantarjianH. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med1992;117:466469.

    • Search Google Scholar
    • Export Citation
  • 37

    O’BrienSKantarjianHBeranM. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood1993;82:16951700.

    • Search Google Scholar
    • Export Citation
  • 38

    Genzyme Corporation. Prescribing Information. Campath (alemtuzumab) Injection for Intravenous Use. Available at: http://www.campath.com/pdfs/2009-08-Campath%20US%20PI.pdf. Accessed October 16 2012.

    • Search Google Scholar
    • Export Citation
  • 39

    HillmenPSkotnickiABRobakT. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol2007;25:56165623.

    • Search Google Scholar
    • Export Citation
  • 40

    MoretonPKennedyBLucasG. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol2005;23:29712979.

    • Search Google Scholar
    • Export Citation
  • 41

    StilgenbauerSZenzTWinklerD. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol2009;27:39944001.

    • Search Google Scholar
    • Export Citation
  • 42

    KeatingMJFlinnIJainV. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood2002;99:35543561.

    • Search Google Scholar
    • Export Citation
  • 43

    ThurskyKAWorthLJSeymourJF. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br J Haematol2006;132:312.

    • Search Google Scholar
    • Export Citation
  • 44

    LaurentiLPiccioniPCattaniP. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica2004;89:12481252.

    • Search Google Scholar
    • Export Citation
  • 45

    NguyenDDCaoTMDuganK. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma2002;3:105110.

    • Search Google Scholar
    • Export Citation
  • 46

    O’BrienSRavandiFRiehlT. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood2008;111:18161819.

    • Search Google Scholar
    • Export Citation
  • 47

    SandherrMEinseleHHebartH. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol2006;17:10511059.

    • Search Google Scholar
    • Export Citation
  • 48

    GlaxoSmithKline. Prescribing Information. ARZERRA (ofatumumab) Injection for Intravenous Infusion. Available at: http://us.gsk.com/products/assets/us_arzerra.pdf. Accessed October 16 2012.

    • Search Google Scholar
    • Export Citation
  • 49

    Genentech Inc.Prescribing Information. Rituxan (rituximab) Injection for Intravenous Use. Available at: http://www.gene.com/gene/products/information/pdf/rituxan-prescribing.pdf. Accessed April.

    • Search Google Scholar
    • Export Citation
  • 50

    DerviteIHoberDMorelP. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med2001;344:6869.

    • Search Google Scholar
    • Export Citation
  • 51

    KimEBKimDSParkSJ. Hepatitis B virus reactivation in a surface antigen-negative and antibody-positive patient after rituximab plus CHOP chemotherapy. Cancer Res Treat2008;40:3638.

    • Search Google Scholar
    • Export Citation
  • 52

    KooYXTayMTehYE. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol2011;90:12191223.

    • Search Google Scholar
    • Export Citation
  • 53

    MatsueKKimuraSTakanashiY. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer2010;116:47694776.

    • Search Google Scholar
    • Export Citation
  • 54

    NiitsuNHagiwaraYTanaeK. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol2010;28:50975100.

    • Search Google Scholar
    • Export Citation
  • 55

    PeiSNChenCHLeeCM. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol2010;89:255262.

    • Search Google Scholar
    • Export Citation
  • 56

    CarsonKREvensAMRicheyEA. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood2009;113:48344840.

    • Search Google Scholar
    • Export Citation
  • 57

    D’SouzaAWilsonJMukherjeeSJaiyesimiI. Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia: a report of three cases and review of the literature. Clin Lymphoma Myeloma Leuk2010;10:E19.

    • Search Google Scholar
    • Export Citation
  • 58

    HopfingerGPlesslAGrisoldW. Progressive multifocal leukoencephalopathy after rituximab in a patient with relapsed follicular lymphoma and low IgG levels and a low CD4+ lymphocyte count. Leuk Lymphoma2008;49:23672369.

    • Search Google Scholar
    • Export Citation
  • 59

    PauesJVrethemM. Fatal progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma treated with rituximab. J Clin Virol2010;48:291293.

    • Search Google Scholar
    • Export Citation
  • 60

    ReddyNAbelTWJagasiaM. Progressive multifocal leukoencephalopathy in a patient with follicular lymphoma treated with multiple courses of rituximab. Leuk Lymphoma2009;50:460462.

    • Search Google Scholar
    • Export Citation
  • 61

    ReyJBelmecheriNBouayedN. JC papovavirus leukoencephalopathy after first line treatment with CHOP and rituximab. Haematologica2007;92:e101.

    • Search Google Scholar
    • Export Citation
  • 62

    TuccoriMFocosiDMaggiF. Progressive multifocal leukoencephalopathy: a report of three cases in HIV-negative patients with non-Hodgkin’s lymphomas treated with rituximab. Ann Hematol2010;89:519522.

    • Search Google Scholar
    • Export Citation
  • 63

    YokoyamaHWatanabeTMaruyamaD. Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature. Int J Hematol2008;88:443447.

    • Search Google Scholar
    • Export Citation
  • 64

    CrippaFHolmbergLCarterRA. Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. Biol Blood Marrow Transplant2002;8:281289.

    • Search Google Scholar
    • Export Citation
  • 65

    RapoportAPMiller WateletLFLinderT. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol1999;17:24462453.

    • Search Google Scholar
    • Export Citation
  • 66

    RuescherTJSodeifiAScrivaniSJ. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer1998;82:22752281.

    • Search Google Scholar
    • Export Citation
  • 67

    SonisSTOsterGFuchsH. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol2001;19:22012205.

    • Search Google Scholar
    • Export Citation
  • 68

    StrakaCSandherrMSalwenderH. Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy. Blood2011;117:21212128.

    • Search Google Scholar
    • Export Citation
  • 69

    MackallCFryTGressR. Background to hematopoietic cell transplantation, including post transplant immune recovery. Bone Marrow Transplant2009;44:457462.

    • Search Google Scholar
    • Export Citation
  • 70

    TomblynMChillerTEinseleH. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant2009;15:11431238.

    • Search Google Scholar
    • Export Citation
  • 71

    WinstonDJSchiffmanGWangDC. Pneumococcal infections after human bone-marrow transplantation. Ann Intern Med1979;91:835841.

  • 72

    KulkarniSPowlesRTreleavenJ. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood2000;95:36833686.

    • Search Google Scholar
    • Export Citation
  • 73

    MeijerEDekkerAWRozenberg-ArskaM. Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors. Clin Infect Dis2002;35:703712.

    • Search Google Scholar
    • Export Citation
  • 74

    MarrKACarterRABoeckhM. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood2002;100:43584366.

    • Search Google Scholar
    • Export Citation
  • 75

    MarrKASeidelKWhiteTCBowdenRA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis2000;181:309316.

    • Search Google Scholar
    • Export Citation
  • 76

    EngelsEALauJBarzaM. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol1998;16:11791187.

    • Search Google Scholar
    • Export Citation
  • 77

    BowEJRaynerELouieTJ. Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis. Am J Med1988;84:847854.

    • Search Google Scholar
    • Export Citation
  • 78

    EltingLSBodeyGPKeefeBH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis1992;14:12011207.

    • Search Google Scholar
    • Export Citation
  • 79

    RazonableRRLitzowMRKhaliqY. Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis2002;34:14691474.

    • Search Google Scholar
    • Export Citation
  • 80

    Eleutherakis-PapaiakovouEKostisEMigkouM. Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial. Am J Hematol2010;85:863867.

    • Search Google Scholar
    • Export Citation
  • 81

    Gafter-GviliAFraserAPaulMLeiboviciL. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med2005;142:979995.

    • Search Google Scholar
    • Export Citation
  • 82

    Gafter-GviliAPaulMFraserALeiboviciL. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother2007;59:522.

    • Search Google Scholar
    • Export Citation
  • 83

    Gafter-GviliAFraserAPaulM. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev2012;1:CD004386.

    • Search Google Scholar
    • Export Citation
  • 84

    BucaneveGMicozziAMenichettiF. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med2005;353:977987.

    • Search Google Scholar
    • Export Citation
  • 85

    CullenMStevenNBillinghamL. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med2005;353:988998.

    • Search Google Scholar
    • Export Citation
  • 86

    CullenMHBillinghamLJGauntCHStevenNM. Rational selection of patients for antibacterial prophylaxis after chemotherapy. J Clin Oncol2007;25:48214828.

    • Search Google Scholar
    • Export Citation
  • 87

    BartlettJGPerlTM. The new Clostridium difficile—what does it mean?N Engl J Med2005;353:25032505.

  • 88

    CookPPCatrouPGoochMHolbertD. Effect of reduction in ciprofloxacin use on prevalence of meticillin-resistant Staphylococcus aureus rates within individual units of a tertiary care hospital. J Hosp Infect2006;64:348351.

    • Search Google Scholar
    • Export Citation
  • 89

    LooVGPoirierLMillerMA. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med2005;353:24422449.

    • Search Google Scholar
    • Export Citation
  • 90

    McDonaldLCKillgoreGEThompsonA. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med2005;353:24332441.

  • 91

    EngelhardDCordonnierCShawPJ. Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol2002;117:444450.

    • Search Google Scholar
    • Export Citation
  • 92

    YoussefSRodriguezGRolstonKV. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989–2005. Medicine (Baltimore)2007;86:6977.

    • Search Google Scholar
    • Export Citation
  • 93

    EngelhardDAkovaMBoeckhMJ. Bacterial infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant2009;44:467470.

    • Search Google Scholar
    • Export Citation
  • 94

    BrownSDRybakMJ. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001–2002, as part of the PROTEKT US study. J Antimicrob Chemother2004;54(Suppl 1):i715.

    • Search Google Scholar
    • Export Citation
  • 95

    KumashiPGirgawyETarrandJJ. Streptococcus pneumoniae bacteremia in patients with cancer: disease characteristics and outcomes in the era of escalating drug resistance (1998–2002). Medicine (Baltimore)2005;84:303312.

    • Search Google Scholar
    • Export Citation
  • 96

    Recommended adult immunization schedule: United States, 2012. Ann Intern Med2012;156:211217.

  • 97

    GoodmanJLWinstonDJGreenfieldRA. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med1992;326:845851.

    • Search Google Scholar
    • Export Citation
  • 98

    SlavinMAOsborneBAdamsR. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J Infect Dis1995;171:15451552.

    • Search Google Scholar
    • Export Citation
  • 99

    MarrKASeidelKSlavinMA. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood2000;96:20552061.

    • Search Google Scholar
    • Export Citation
  • 100

    RotsteinCBowEJLaverdiereM. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis1999;28:331340.

    • Search Google Scholar
    • Export Citation
  • 101

    KernWBehreGRudolfT. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group. Cancer1998;83:291301.

    • Search Google Scholar
    • Export Citation
  • 102

    WinstonDJChandrasekarPHLazarusHM. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med1993;118:495503.

    • Search Google Scholar
    • Export Citation
  • 103

    BodeyGPMardaniMHannaHA. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med2002;112:380385.

    • Search Google Scholar
    • Export Citation
  • 104

    KohLPKurupAGohYT. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol2002;71:260267.

    • Search Google Scholar
    • Export Citation
  • 105

    MarrKACrippaFLeisenringW. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood2004;103:15271533.

    • Search Google Scholar
    • Export Citation
  • 106

    WinstonDJMaziarzRTChandrasekarPH. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med2003;138:705713.

    • Search Google Scholar
    • Export Citation
  • 107

    MarrKALeisenringWCrippaF. Cyclophosphamide metabolism is affected by azole antifungals. Blood2004;103:15571559.

  • 108

    BatesDWSuLYuDT. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int2001;60:14521459.

  • 109

    WingardJRKubilisPLeeL. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis1999;29:14021407.

    • Search Google Scholar
    • Export Citation
  • 110

    RijndersBJCornelissenJJSlobbeL. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis2008;46:14011408.

    • Search Google Scholar
    • Export Citation
  • 111

    PerfectJR. Aerosolized antifungal prophylaxis: the winds of change?Clin Infect Dis2008;46:14091411.

  • 112

    Astellas Pharma Inc.Prescribing Information. MYCAMINE (micafungin sodium) For Injection; IV Infusion Only. Available at: http://www.astellas.us/docs/mycamine.pdf. Accessed October 16 2012.

    • Search Google Scholar
    • Export Citation
  • 113

    van BurikJARatanatharathornVStepanDE. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis2004;39:14071416.

    • Search Google Scholar
    • Export Citation
  • 114

    WingardJRCarterSLWalshTJ. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood2010;116:51115118.

    • Search Google Scholar
    • Export Citation
  • 115

    CowenEWNguyenJCMillerDD. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol2010;62:3137.

    • Search Google Scholar
    • Export Citation
  • 116

    McCarthyKLPlayfordEGLookeDFWhitbyM. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis2007;44:e5556.

    • Search Google Scholar
    • Export Citation
  • 117

    MillerDDCowenEWNguyenJC. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol2010;146:300304.

    • Search Google Scholar
    • Export Citation
  • 118

    KrishnaGMotonAMaL. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother2009;53:958966.

    • Search Google Scholar
    • Export Citation
  • 119

    VazquezJASkiestDJNietoL. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis2006;42:11791186.

    • Search Google Scholar
    • Export Citation
  • 120

    CornelyOAMaertensJWinstonDJ. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med2007;356:348359.

    • Search Google Scholar
    • Export Citation
  • 121

    Schering Corporation subsidiary of Merck & Co Inc.Prescribing Information. NOXAFIL® (Posaconazole) ORAL SUSPENSION 40 mg/mL. Available at: http://www.spfiles.com/pinoxafil.pdf. Accessed October 16 2012.

    • Search Google Scholar
    • Export Citation
  • 122

    BohmeAJust-NublingGBergmannL. Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. J Antimicrob Chemother1996;38:953961.

    • Search Google Scholar
    • Export Citation
  • 123

    Pfizer Inc.Prescribing Information. VFEND® (voriconazole) Tablets Oral Suspension and I.V. Available at: http://www.pfizer.com/files/products/uspi_vfend.pdf. Accessed October 16 2012.

    • Search Google Scholar
    • Export Citation
  • 124

    WeinbergerMElattarIMarshallD. Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine (Baltimore)1992;71:2443.

    • Search Google Scholar
    • Export Citation
  • 125

    UllmannAJLiptonJHVesoleDH. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med2007;356:335347.

    • Search Google Scholar
    • Export Citation
  • 126

    WalshTJWhitcombPORevankarSGPizzoPA. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer1995;76:23572362.

    • Search Google Scholar
    • Export Citation
  • 127

    OffnerFCordonnierCLjungmanP. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis1998;26:10981103.

    • Search Google Scholar
    • Export Citation
  • 128

    FukudaTBoeckhMGuthrieKA. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant2004;10:494503.

    • Search Google Scholar
    • Export Citation
  • 129

    MeyersJDFlournoyNThomasED. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis1980;142:338346.

    • Search Google Scholar
    • Export Citation
  • 130

    SaralRBurnsWHLaskinOL. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med1981;305:6367.

  • 131

    SaralRAmbinderRFBurnsWH. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med1983;99:773776.

    • Search Google Scholar
    • Export Citation
  • 132

    ZaiaJBadenLBoeckhMJ. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant2009;44:471482.

  • 133

    KeatingMCoutreSRaiK. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma2004;4:220227.

    • Search Google Scholar
    • Export Citation
  • 134

    BoeckhMKimHWFlowersME. Long–term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation—a randomized double-blind placebo-controlled study. Blood2006;107:18001805.

    • Search Google Scholar
    • Export Citation
  • 135

    ErardVGuthrieKAVarleyC. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood2007;110:30713077.

    • Search Google Scholar
    • Export Citation
  • 136

    Asano-MoriYKandaYOshimaK. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol2008;83:472476.

    • Search Google Scholar
    • Export Citation
  • 137

    OshimaKTakahashiTMoriT. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group. Transpl Infect Dis2010;12:421427.

    • Search Google Scholar
    • Export Citation
  • 138

    SchuchterLMWingardJRPiantadosiS. Herpes zoster infection after autologous bone marrow transplantation. Blood1989;74:14241427.

  • 139

    Chanan-KhanASonneveldPSchusterMW. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol2008;26:47844790.

    • Search Google Scholar
    • Export Citation
  • 140

    ReeceDERodriguezGPChenC. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol2008;26:47774783.

    • Search Google Scholar
    • Export Citation
  • 141

    TongYQianJLiY. The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients. Am J Hematol2007;82:403404.

  • 142

    VarettoniMVassalloCBorroniG. Late onset of bortezomib-associated cutaneous reaction following herpes zoster. Ann Hematol2007;86:301302.

    • Search Google Scholar
    • Export Citation
  • 143

    PourLAdamZBuresovaL. Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma2009;9:151153.

    • Search Google Scholar
    • Export Citation
  • 144

    VickreyEAllenSMehtaJSinghalS. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer2009;115:229232.

    • Search Google Scholar
    • Export Citation
  • 145

    GeorgeBPatiNGilroyN. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis2010;12:322329.

    • Search Google Scholar
    • Export Citation
  • 146

    BeckJCWagnerJEDeForTE. Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation. Biol Blood Marrow Transplant2010;16:215222.

    • Search Google Scholar
    • Export Citation
  • 147

    MilanoFPergamSAXieH. Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood2011;118:56895696.

    • Search Google Scholar
    • Export Citation
  • 148

    MontesinosPSanzJCanteroS. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. Biol Blood Marrow Transplant2009;15:730740.

    • Search Google Scholar
    • Export Citation
  • 149

    PrenticeHGKhoP. Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant. Bone Marrow Transplant1997;19:135142.

    • Search Google Scholar
    • Export Citation
  • 150

    MorettiSZikosPVan LintMT. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study. Bone Marrow Transplant1998;22:175180.

    • Search Google Scholar
    • Export Citation
  • 151

    ReusserPEinseleHLeeJ. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood2002;99:11591164.

    • Search Google Scholar
    • Export Citation
  • 152

    LjungmanPDeliliersGLPlatzbeckerU. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood2001;97:388392.

    • Search Google Scholar
    • Export Citation
  • 153

    PlatzbeckerUBandtDThiedeC. Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation. Transplantation2001;71:880885.

    • Search Google Scholar
    • Export Citation
  • 154

    MeyersJDReedECSheppDH. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med1988;318:7075.

    • Search Google Scholar
    • Export Citation
  • 155

    PrenticeHGGluckmanEPowlesRL. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet1994;343:749753.

    • Search Google Scholar
    • Export Citation
  • 156

    LjungmanPde La CamaraRMilpiedN. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood2002;99:30503056.

    • Search Google Scholar
    • Export Citation
  • 157

    GentileGPicardiACapobianchiA. A prospective study comparing quantitative Cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation. BMC Infect Dis2006;6:167.

    • Search Google Scholar
    • Export Citation
  • 158

    GimenoCSolanoCLatorreJC. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J Clin Microbiol2008;46:33113318.

    • Search Google Scholar
    • Export Citation
  • 159

    SolanoCMunozIGutierrezA. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation. J Clin Microbiol2001;39:39383941.

    • Search Google Scholar
    • Export Citation
  • 160

    EinseleHReusserPBornhauserM. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood2006;107:30023008.

    • Search Google Scholar
    • Export Citation
  • 161

    WinstonDJBadenLRGabrielDA. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Biol Blood Marrow Transplant2006;12:635640.

    • Search Google Scholar
    • Export Citation
  • 162

    AyalaEGreeneJSandinR. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant2006;37:851856.

    • Search Google Scholar
    • Export Citation
  • 163

    BuscaAde FabritiisPGhisettiV. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation. Transpl Infect Dis2007;9:102107.

    • Search Google Scholar
    • Export Citation
  • 164

    van der HeidenPLKalpoeJSBargeRM. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant2006;37:693698.

    • Search Google Scholar
    • Export Citation
  • 165

    BosiABartolozziBVannucchiAM. Polymerase chain reaction-based ”pre-emptive” therapy with cidofovir for cytomegalovirus reactivation in allogeneic hematopoietic stem cells transplantation recipients: a prospective study. Haematologica2002;87:446447.

    • Search Google Scholar
    • Export Citation
  • 166

    ChakrabartiSCollinghamKEOsmanH. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections. Bone Marrow Transplant2001;28:879881.

    • Search Google Scholar
    • Export Citation
  • 167

    WinstonDJYoungJAPullarkatV. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood2008;111:54035410.

    • Search Google Scholar
    • Export Citation
  • 168

    MartyFMLjungmanPPapanicolaouGA. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis2011;11:284292.

    • Search Google Scholar
    • Export Citation
  • 169

    NguyenQChamplinRGiraltS. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis1999;28:618623.

    • Search Google Scholar
    • Export Citation
  • 170

    BoeckhMLeisenringWRiddellSR. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood2003;101:407414.

    • Search Google Scholar
    • Export Citation
  • 171

    HakkiMRiddellSRStorekJ. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood2003;102:30603067.

    • Search Google Scholar
    • Export Citation
  • 172

    GratamaJWvan EsserJWLamersCH. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood2001;98:13581364.

    • Search Google Scholar
    • Export Citation
  • 173

    OzdemirESt JohnLSGillespieG. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood2002;100:36903697.

    • Search Google Scholar
    • Export Citation
  • 174

    MontilloMSchinkoetheTElterT. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome. Cancer Invest2005;23:488496.

    • Search Google Scholar
    • Export Citation
  • 175

    O’BrienSMKeatingMJMocarskiES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma2006;7:125130.

    • Search Google Scholar
    • Export Citation
  • 176

    YeoWChanPKHoWM. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol2004;22:927934.

    • Search Google Scholar
    • Export Citation
  • 177

    SeraTHiasaYMichitakaK. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med2006;45:721724.

    • Search Google Scholar
    • Export Citation
  • 178

    WasmuthJCFischerHPSauerbruchTDumoulinFL. Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphamide/rituximab for low grade non-Hodgkin’s lymphoma. Eur J Med Res2008;13:483486.

    • Search Google Scholar
    • Export Citation
  • 179

    WesthoffTHJochimsenFSchmittelA. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood2003;102:1930.

    • Search Google Scholar
    • Export Citation
  • 180

    YeoWChanPKZhongS. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol2000;62:299307.

    • Search Google Scholar
    • Export Citation
  • 181

    LiangR. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood2009;113:31473153.

    • Search Google Scholar
    • Export Citation
  • 182

    BrechotCDegosFLugassyC. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med1985;312:270276.

    • Search Google Scholar
    • Export Citation
  • 183

    DhedinNDouvinCKuentzM. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation1998;66:616619.

    • Search Google Scholar
    • Export Citation
  • 184

    EvensAMJovanovicBDSuYC. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol2011;22:11701180.

    • Search Google Scholar
    • Export Citation
  • 185

    ViganoMVenerCLamperticoP. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant2011;46:125131.

    • Search Google Scholar
    • Export Citation
  • 186

    HammondSPBorcheltAMUkomaduC. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant2009;15:10491059.

    • Search Google Scholar
    • Export Citation
  • 187

    LokASMcMahonBJ. Chronic hepatitis B. Hepatology2007;45:507539.

  • 188

    GhanyMGStraderDBThomasDLSeeffLB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology2009;49:13351374.

  • 189

    GiacconeLFestucciaMMarengoA. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant2010;16:809817.

    • Search Google Scholar
    • Export Citation
  • 190

    LauGKHeMLFongDY. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology2002;36:702709.

    • Search Google Scholar
    • Export Citation
  • 191

    RossiGPelizzariAMottaMPuotiM. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol2001;115:5862.

    • Search Google Scholar
    • Export Citation
  • 192

    ZiakasPDKarsaliakosPMylonakisE. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica2009;94:9981005.

    • Search Google Scholar
    • Export Citation
  • 193

    CortelezziAViganoMZilioliVR. Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. J Clin Virol2006;35:467469.

    • Search Google Scholar
    • Export Citation
  • 194

    PetersMGHann HwHMartinP. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology2004;126:91101.

    • Search Google Scholar
    • Export Citation
  • 195

    MarcellinPHeathcoteEJButiM. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med2008;359:24422455.

    • Search Google Scholar
    • Export Citation
  • 196

    LeungNPengCYHannHW. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology2009;49:7279.

    • Search Google Scholar
    • Export Citation
  • 197

    ChanHLHeathcoteEJMarcellinP. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med2007;147:745754.

    • Search Google Scholar
    • Export Citation
  • 198

    LjungmanPCordonnierCEinseleH. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant2009;44:521526.

  • 199

    KrogerATAtkinsonWLMarcuseEKPickeringLK. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep2006;55:148.

    • Search Google Scholar
    • Export Citation
  • 200

    OrtbalsDWLiebhaberHPresantCA. Influenza immunization of adult patients with malignant diseases. Ann Intern Med1977;87:552557.

  • 201

    SommerALWachelBKSmithJA. Evaluation of vaccine dosing in patients with solid tumors receiving myelosuppressive chemotherapy. J Oncol Pharm Pract2006;12:143154.

    • Search Google Scholar
    • Export Citation
  • 202

    BowdenRA. Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience. Am J Med1997;102:2730.

    • Search Google Scholar
    • Export Citation
  • 203

    LjungmanP. Respiratory virus infections in stem cell transplant patients: the European experience. Biol Blood Marrow Transplant2001;7Suppl:5S7S.

    • Search Google Scholar
    • Export Citation
  • 204

    WhimbeyEChamplinRECouchRB. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis1996;22:778782.

    • Search Google Scholar
    • Export Citation
  • 205

    FeldmanSWebsterRGSuggM. Influenza in children and young adults with cancer: 20 cases. Cancer1977;39:350353.

  • 206

    KempeAHallCBMacDonaldNE. Influenza in children with cancer. J Pediatr1989;115:3339.

  • 207

    EltingLSWhimbeyELoW. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Support Care Cancer1995;3:198202.

    • Search Google Scholar
    • Export Citation
  • 208

    FioreAEUyekiTMBroderK. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep2010;59:162.

    • Search Google Scholar
    • Export Citation
  • 209

    HarperSAFukudaKCoxNJBridgesCB. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep2003;52:18.

    • Search Google Scholar
    • Export Citation
  • 210

    BransonBMHandsfieldHHLampeMA. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep2006;55:117; quiz CE11–14.

    • Search Google Scholar
    • Export Citation
  • 211

    GreenHPaulMVidalLLeiboviciL. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc2007;82:10521059.

    • Search Google Scholar
    • Export Citation
  • 212

    HughesWTKuhnSChaudharyS. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med1977;297:14191426.

  • 213

    HughesWTRiveraGKSchellMJ. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med1987;316:16271632.

    • Search Google Scholar
    • Export Citation
  • 214

    LindemulderSAlbanoE. Successful intermittent prophylaxis with trimethoprim/sulfamethoxazole 2 days per week for Pneumocystis carinii (jiroveci) pneumonia in pediatric oncology patients. Pediatrics2007;120:e4751.

    • Search Google Scholar
    • Export Citation
  • 215

    MarrKABowEChillerT. Fungal infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant2009;44:483487.

  • 216

    MarrasTKSandersKLiptonJH. Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation. Transpl Infect Dis2002;4:6674.

    • Search Google Scholar
    • Export Citation
  • 217

    SangioloDStorerBNashR. Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study. Biol Blood Marrow Transplant2005;11:521529.

    • Search Google Scholar
    • Export Citation
  • 218

    SouzaJPBoeckhMGooleyTA. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clin Infect Dis1999;29:14671471.

    • Search Google Scholar
    • Export Citation
  • 219

    VasconcellesMJBernardoMVKingC. Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant2000;6:3543.

    • Search Google Scholar
    • Export Citation
  • 220

    El-SadrWMMurphyRLYurikTM. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med1998;339:18891895.

    • Search Google Scholar
    • Export Citation
  • 221

    MaddenRMPuiCHHughesWT. Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia. Cancer2007;109:16541658.

    • Search Google Scholar
    • Export Citation
  • 222

    Schering Corporation a subsidiary of Merck & Co Inc.Prescribing Information. TEMODAR (temozolomide) Capsules; TEMODAR (temozolomide) for Injection Administered Via Intravenous Infusion. Available at: http://www.spfiles.com/pitemodar.pdf. Accessed October 16 2012.

    • Search Google Scholar
    • Export Citation
  • 223

    KritzASepkowitzKWeissM. Pneumocystis carinii pneumonia developing within one month of intensive chemotherapy for treatment of acute lymphoblastic leukemia. N Engl J Med1991;325:661662.

    • Search Google Scholar
    • Export Citation
  • 224

    SepkowitzKA. Pneumocystis carinii pneumonia among patients with neoplastic disease. Semin Respir Infect1992;7:114121.

  • 225

    SepkowitzKA. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis1993;17(Suppl 2):S416422.

  • 226

    SepkowitzKABrownAETelzakEE. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA1992;267:832837.

  • 227

    HahnTCummingsKMMichalekAM. Efficacy of high-efficiency particulate air filtration in preventing aspergillosis in immunocompromised patients with hematologic malignancies. Infect Control Hosp Epidemiol2002;23:525531.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 791 791 106
PDF Downloads 198 198 33
EPUB Downloads 0 0 0